Skip to main content

Table 1 Biochemical indicators of patients (blood lipids, liver function and blood sugar), B-ultrasound, TCM symptom and signs score before treatment (baseline) and after 16 weeks of treatment

From: Danshao Shugan Granule therapy for non-alcoholic fatty liver disease

   Ros Sil DSSG P-value
among three groups
DSSG + Sil P-value
(Sil vs DSSG + Sil)
P-value
(DSSG vs DSSG + Sil)
Number   30 50 130   50   
TC (mmol/L) Pre- treatment 6.55 ± 0.19 6.56 ± 0.28 6.46 ± 0.55 0.340 6.50 ± 0.46  > 0.05  > 0.05
Post treatment 5.85 ± 0.15 6.41 ± 0.23 4.97 ± 0.33   6.02 ± 0.28   
  Δ -0.69 ± 0.29 -0.15 ± 0.29 -1.56 ± 0.95  < 0.05 -0.48 ± 0.41  > 0.05  < 0.05
TG (mmol/L) Pre- treatment 2.83 ± 0.13 2.80 ± 0.59 2.72 ± 0.90 0.695 3.03 ± 0.71  > 0.05  > 0.05
Post treatment 2.26 ± 0.09 2.32 ± 0.51 1.80 ± 0.24   2.30 ± 0.41   
  Δ -0.57 ± 0.60 -0.48 ± 0.67 -0.99 ± 1.09  < 0.05 -0.73 ± 0.68  > 0.05  > 0.05
ALT (U/L) Pre- treatment 76.84 ± 3.51 75.41 ± 6.99 74.98 ± 16.39 0.792 76.47 ± 8.60  > 0.05  > 0.05
Post treatment 71.18 ± 4.12 38.96 ± 4.51 44.01 ± 6.06   36.94 ± 4.01   
  Δ -5.66 ± 13.37 -36.45 ± 5.80 -32.78 ± 25.42  < 0.05 -39.53 ± 8.34  > 0.05  > 0.05
AST (U/L) Pre- treatment 72.42 ± 2.69 74.21 ± 8.27 73.08 ± 16.16 0.822 76.99 ± 12.02  > 0.05  > 0.05
Post treatment 62.41 ± 2.32 54.20 ± 7.73 42.24 ± 4.96   53.26 ± 8.23   
  Δ -10.01 ± 17.60 -20.01 ± 8.84 -32.02 ± 19.73  < 0.05 -23.73 ± 8.31  > 0.05  < 0.05
GGT (U/L) Pre- treatment 71.02 ± 3.28 74.99 ± 9.08 76.40 ± 10.64  < 0.05 76.43 ± 9.95  > 0.05  > 0.05
Post treatment 47.20 ± 2.54 64.26 ± 7.68 47.58 ± 6.21   60.09 ± 6.30   
  Δ -23.82 ± 13.97 -10.72 ± 10.79 -31.72 ± 18.89  < 0.05 -16.34 ± 8.31  > 0.05  > 0.05
FPG (mmol/L) Pre- treatment 6.09 ± 0.14 6.03 ± 0.29 5.89 ± 0.72 0.139 6.02 ± 0.36  > 0.05  > 0.05
Post treatment 4.26 ± 0.08 5.76 ± 0.29 5.52 ± 0.58   5.63 ± 0.31   
  Δ -1.83 ± 1.19 -0.27 ± 0.28 -0.36 ± 0.72  < 0.05 -0.39 ± 0.36  > 0.05  > 0.05
B-ultrasonography Cure 4 (13.0%) 1 (2.0%) 40 (31.0%)  < 0.05 5 (10.0%)  > 0.05  < 0.05
  Obviously effective 12 (40.0%) 4 (8.0%) 32 (24.5%)  < 0.05 11 (22.0%)  < 0.05  > 0.05
  Effective 8 (27.0%) 24 (48.0%) 47 (36.0%) 0.139 23 (46.0%)  > 0.05  > 0.05
  Non-effective 6 (20.0%) 21 (42.0%) 11 (8.5%)  < 0.05 11 (22.0%)  < 0.05  < 0.05
  Effective rate 24 (80.0%) 29 (58.0%) 119 (91.5%)  < 0.05 39 (78.0%)  < 0.05  < 0.05
TCM symptom and signs score Pre- treatment 14.00 ± 0.51 13.92 ± 2.39 13.72 ± 1.10 0.529 14.76 ± 2.60  > 0.05  < 0.05
  Post treatment 3.00 ± 0.31 9.10 ± 1.95 2.41 ± 0.43  < 0.05 5.04 ± 2.27  < 0.05  < 0.05
  Δ -11.00 ± 0.20 -4.82 ± 0.44 -11.31 ± 0.67  < 0.05 -9.72 ± 0.33  < 0.05  < 0.05
  1. Note: If the measured data were normally distributed, the mean ± standard deviation (SD) was used. Single factor variance analysis was used to make pairwise comparison among multiple groups. The test level was α = 0.05 and a P-value < 0.05 was considered to be statistically significant. Δ, value change before and after the rosiglitazone, Silibinin and DSSG treatments for the TCM symptoms and sign scores to compare the TCM syndrome. Group Ros: Rosiglitazone hydrochloride, 4 mg/time, once a day. Group Sil: Silibinin capsules, orally, 3 × 35 mg containing capsules, 3 times a day. Group DSSG: Patients received DSSG, 12 g/packages, each containing the above dose proportions; 2 packages/time, were administered 3 times a day. Group DSSG + Sil: DSSG (orally, 2 packages, 3 times a day) + Silibinin capsules (orally, 3 tablets, 3 times a day)
  2. ALT alanine aminotransferase, AST aspartate amino transferase, DSSG Danshao Shugan Granules, FPG Fasting plasma glucose, GGT γ-glutamyl transpeptidase, TC total cholesterol, TCM traditional Chinese medicine, TG triacylglycerol